Market Cap 651.74M
Revenue (ttm) 0.00
Net Income (ttm) -174.33M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 969,300
Avg Vol 1,135,026
Day's Range N/A - N/A
Shares Out 98.45M
Stochastic %K 32%
Beta 2.47
Analysts Strong Sell
Price Target $17.00

Company Profile

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, wh...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 337 4680
Address:
500 Rutherford Avenue, Third Floor, Charlestown, United States
diggs24
diggs24 May. 20 at 12:27 PM
$SLDB Added 800 yesterday
0 · Reply
SuperGreenToday
SuperGreenToday May. 19 at 10:31 PM
$SLDB Share Price: $6.09 Contract Selected: Dec 18, 2026 $3.0 Calls Buy Zone: $1.27 – $1.58 Target Zone: $2.07 – $2.53 Potential Upside: 53% ROI Time to Expiration: 212 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
danieltanner
danieltanner May. 19 at 1:33 PM
$SLDB everything adding Hands over rod?
0 · Reply
Jonrenie
Jonrenie May. 19 at 5:37 AM
$SLDB slowly accumulating
0 · Reply
diggs24
diggs24 May. 18 at 10:00 PM
$SLDB Added 375 more shares today.
0 · Reply
BluntForceOptions
BluntForceOptions May. 16 at 5:32 AM
$SLDB Technical Breakdown & Structural Topping Pattern in Focus The macro backdrop across the small-cap biotech space took a definitive hit in today's session. Re-emerging inflation anxieties and rising bond yields triggered a broad-based sector flush, forcing extended names to face technical realities. Looking at the daily chart for SLDB, the price action has carved out a textbook Head & Shoulders topping pattern that's actively threatening a major structural shift. Pattern Topology - Left Shoulder: Peak formed in March, putting in local resistance in the $8.50–$8.75 zone. - Head: The absolute peak printed at $8.87 (the 1.0 Fibonacci retracement level) in mid-April. - Right Shoulder: A clear lower-high distribution phase throughout early May, failing below the $8.50 level and confirming exhausting buy-side pressure. The Neckline & Downside Targets Today's -9.31% flush brought SLDB down to a close of $6.92, placing it directly on top of--and arguably breaking--the ascending neckline support. If this neckline fails to hold on a daily closing basis, momentum shifts decisively to the bears, exposing a clear downside runway to the following keyed support clusters: - S-1 & Moving Average Cluster ($6.41 – $6.18): A clean break below the neckline opens the door straight to the 61.8% Fibonacci retracement level at $6.41. Just below that sits the 200-day SMA at $6.18. Expect price action to gravitate heavily toward this cluster; the 200-day SMA serves as the ultimate line in the sand for the long-term trend. - S-2 (50% Retracement): If the 200-day SMA fails to stem the bleeding, the next structural shelf rests at the 50% Fib level at $5.65. - S-3 & S-4 (Deeper Value Shelves): If a macro-driven liquidation scenario intensifies, deeper structural support lines up at the 38.2% Fib at $4.89 (S-3) and the 23.6% Fib at $3.95 (S-4). The Bottom Line: The pattern structure dictates the bias. Until SLDB can reclaim the breakdown level and stabilize, the path of least resistance remains a gravitational pull into the 200-day SMA liquidity pocket. Respect the breakdown and manage risk accordingly. NFA. Please do your own DD. $XBI $IWM $IBB
0 · Reply
Teillbou
Teillbou May. 15 at 11:26 PM
$SLDB 750M, $RGNX 370M For what exactly? RGX-202 Phase 3 just hit primary endpoint — 93% of patients above 10% microdystrophin expression p<0.0001. Statistically significant correlation with functional improvement. CT domain differentiation. 2+ years safety data. SGT-003 has biomarkers and a Phase 3 that just dosed its first patient — no NSAA, no timed tests published. Results won't come before 2028 at best. Market punishing RGNX on cash and FDA execution — fair. But $100M AbbVie coming Q2, wet AMD readout Q4. You're paying ~$120M above cash for all of that. SLDB you're paying $370M above cash for Phase 3 data years away. Make it make sense. $SLDB $DMD.X
2 · Reply
diggs24
diggs24 May. 15 at 8:44 PM
$SLDB 12714@$3.39
0 · Reply
millionaire2021
millionaire2021 May. 15 at 8:39 PM
$SLDB may I please ask your average ?
0 · Reply
diggs24
diggs24 May. 15 at 5:57 PM
$SLDB Added another 300 as it fell today. Up to 12,700 shares.
0 · Reply
Latest News on SLDB
Solid Biosciences Quarterly report: Q1 2026

May 12, 2026, 7:00 AM EDT - 14 days ago

Solid Biosciences Quarterly report: Q1 2026


Solid Biosciences Earnings release: Q1 2026

May 12, 2026, 7:00 AM EDT - 14 days ago

Solid Biosciences Earnings release: Q1 2026


Solid Biosciences Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 4 weeks ago

Solid Biosciences Proxy statement: Proxy filing


Solid Biosciences Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 4 weeks ago

Solid Biosciences Proxy statement: Proxy filing


Solid Biosciences Proxy statement: Proxy filing

Apr 10, 2026, 8:00 AM EDT - 6 weeks ago

Solid Biosciences Proxy statement: Proxy filing


Solid Biosciences initiated with a Buy at Guggenheim

2026-03-20T10:31:13.000Z - 2 months ago

Solid Biosciences initiated with a Buy at Guggenheim


Solid Biosciences reports Q4 EPS (53c), consensus (52c)

2026-03-19T20:25:28.000Z - 2 months ago

Solid Biosciences reports Q4 EPS (53c), consensus (52c)


Solid Biosciences Registration statement: Registration filing

Mar 19, 2026, 8:00 AM EDT - 2 months ago

Solid Biosciences Registration statement: Registration filing


Solid Biosciences Registration statement: Registration filing

Mar 19, 2026, 8:00 AM EDT - 2 months ago

Solid Biosciences Registration statement: Registration filing


Solid Biosciences Earnings release: Q4 2025

Mar 19, 2026, 7:00 AM EDT - 2 months ago

Solid Biosciences Earnings release: Q4 2025


Solid Biosciences Annual report: Q4 2025

Mar 19, 2026, 7:00 AM EDT - 2 months ago

Solid Biosciences Annual report: Q4 2025


Solid Biosciences trading resumes

2026-03-11T17:30:14.000Z - 2 months ago

Solid Biosciences trading resumes


Solid Biosciences trading halted, news pending

2026-03-11T16:55:13.000Z - 2 months ago

Solid Biosciences trading halted, news pending


Solid Biosciences  participates in a conference call with Cantor

2026-02-03T21:13:24.000Z - 3 months ago

Solid Biosciences participates in a conference call with Cantor


Solid Biosciences Slides: Study presentation

Dec 12, 2025, 4:00 PM EST - 5 months ago

Solid Biosciences Slides: Study presentation


Solid Biosciences Slides: Company presentation

Dec 12, 2025, 2:00 PM EST - 5 months ago

Solid Biosciences Slides: Company presentation


Solid Biosciences Quarterly report: Q3 2025

Nov 3, 2025, 2:00 AM EST - 7 months ago

Solid Biosciences Quarterly report: Q3 2025


Solid Biosciences Earnings release: Q3 2025

Nov 3, 2025, 2:00 AM EST - 7 months ago

Solid Biosciences Earnings release: Q3 2025


Solid Biosciences Slides: Q3 2025

Nov 3, 2025, 2:00 AM EST - 7 months ago

Solid Biosciences Slides: Q3 2025


Solid Biosciences to Present at Upcoming Scientific Meetings

Oct 1, 2025, 8:00 AM EDT - 8 months ago

Solid Biosciences to Present at Upcoming Scientific Meetings


Solid Biosciences Quarterly report: Q2 2025

Aug 12, 2025, 2:30 AM EDT - 10 months ago

Solid Biosciences Quarterly report: Q2 2025


Solid Biosciences Earnings release: Q2 2025

Aug 12, 2025, 2:30 AM EDT - 10 months ago

Solid Biosciences Earnings release: Q2 2025


Solid Biosciences Registration statement: Registration Filing

May 15, 2025, 8:00 AM EDT - 1 year ago

Solid Biosciences Registration statement: Registration Filing


Solid Biosciences Quarterly report: Q1 2025

May 15, 2025, 3:00 AM EDT - 1 year ago

Solid Biosciences Quarterly report: Q1 2025


Solid Biosciences Earnings release: Q1 2025

May 15, 2025, 3:00 AM EDT - 1 year ago

Solid Biosciences Earnings release: Q1 2025


Solid Biosciences Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Solid Biosciences Proxy statement: Proxy Filing


Solid Biosciences Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Solid Biosciences Proxy statement: Proxy Filing


Solid Biosciences Proxy statement: Proxy Filing

Apr 11, 2025, 8:00 AM EDT - 1 year ago

Solid Biosciences Proxy statement: Proxy Filing


Can Solid Biosciences Challenge Sarepta in the DMD Market?

Apr 8, 2025, 7:31 AM EDT - 1 year ago

Can Solid Biosciences Challenge Sarepta in the DMD Market?


Solid Biosciences Annual report: Q4 2024

Mar 6, 2025, 1:30 AM EST - 1 year ago

Solid Biosciences Annual report: Q4 2024


Solid Biosciences Earnings release: Q4 2024

Mar 6, 2025, 1:30 AM EST - 1 year ago

Solid Biosciences Earnings release: Q4 2024


Solid Biosciences Transcript: Study Update

Feb 18, 2025, 8:00 AM EST - 1 year ago

Solid Biosciences Transcript: Study Update


Solid Biosciences Press release: Study Update

Feb 18, 2025, 8:00 AM EST - 1 year ago

Solid Biosciences Press release: Study Update


Solid Biosciences Slides: Study Update

Feb 18, 2025, 8:00 AM EST - 1 year ago

Solid Biosciences Slides: Study Update


Solid Biosciences Announces Pricing of Underwritten Offering

Feb 18, 2025, 7:00 AM EST - 1 year ago

Solid Biosciences Announces Pricing of Underwritten Offering


Solid Biosciences Slides: FY 2025

Jan 15, 2025, 6:45 PM EST - 1 year ago

Solid Biosciences Slides: FY 2025


Solid Biosciences Transcript: FDA Announcement

Jan 8, 2025, 8:30 AM EST - 1 year ago

Solid Biosciences Transcript: FDA Announcement


Solid Biosciences Press release: FDA Announcement

Jan 8, 2025, 8:30 AM EST - 1 year ago

Solid Biosciences Press release: FDA Announcement


Solid Biosciences Slides: FDA Announcement

Jan 8, 2025, 8:30 AM EST - 1 year ago

Solid Biosciences Slides: FDA Announcement


Solid Biosciences Added to the Nasdaq Biotechnology Index

Dec 23, 2024, 4:05 PM EST - 1 year ago

Solid Biosciences Added to the Nasdaq Biotechnology Index


Solid Biosciences Earnings release: Q3 2024

Nov 6, 2024, 1:30 AM EST - 1 year ago

Solid Biosciences Earnings release: Q3 2024


Solid Biosciences Quarterly report: Q3 2024

Nov 6, 2024, 1:30 AM EST - 1 year ago

Solid Biosciences Quarterly report: Q3 2024


diggs24
diggs24 May. 20 at 12:27 PM
$SLDB Added 800 yesterday
0 · Reply
SuperGreenToday
SuperGreenToday May. 19 at 10:31 PM
$SLDB Share Price: $6.09 Contract Selected: Dec 18, 2026 $3.0 Calls Buy Zone: $1.27 – $1.58 Target Zone: $2.07 – $2.53 Potential Upside: 53% ROI Time to Expiration: 212 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
danieltanner
danieltanner May. 19 at 1:33 PM
$SLDB everything adding Hands over rod?
0 · Reply
Jonrenie
Jonrenie May. 19 at 5:37 AM
$SLDB slowly accumulating
0 · Reply
diggs24
diggs24 May. 18 at 10:00 PM
$SLDB Added 375 more shares today.
0 · Reply
BluntForceOptions
BluntForceOptions May. 16 at 5:32 AM
$SLDB Technical Breakdown & Structural Topping Pattern in Focus The macro backdrop across the small-cap biotech space took a definitive hit in today's session. Re-emerging inflation anxieties and rising bond yields triggered a broad-based sector flush, forcing extended names to face technical realities. Looking at the daily chart for SLDB, the price action has carved out a textbook Head & Shoulders topping pattern that's actively threatening a major structural shift. Pattern Topology - Left Shoulder: Peak formed in March, putting in local resistance in the $8.50–$8.75 zone. - Head: The absolute peak printed at $8.87 (the 1.0 Fibonacci retracement level) in mid-April. - Right Shoulder: A clear lower-high distribution phase throughout early May, failing below the $8.50 level and confirming exhausting buy-side pressure. The Neckline & Downside Targets Today's -9.31% flush brought SLDB down to a close of $6.92, placing it directly on top of--and arguably breaking--the ascending neckline support. If this neckline fails to hold on a daily closing basis, momentum shifts decisively to the bears, exposing a clear downside runway to the following keyed support clusters: - S-1 & Moving Average Cluster ($6.41 – $6.18): A clean break below the neckline opens the door straight to the 61.8% Fibonacci retracement level at $6.41. Just below that sits the 200-day SMA at $6.18. Expect price action to gravitate heavily toward this cluster; the 200-day SMA serves as the ultimate line in the sand for the long-term trend. - S-2 (50% Retracement): If the 200-day SMA fails to stem the bleeding, the next structural shelf rests at the 50% Fib level at $5.65. - S-3 & S-4 (Deeper Value Shelves): If a macro-driven liquidation scenario intensifies, deeper structural support lines up at the 38.2% Fib at $4.89 (S-3) and the 23.6% Fib at $3.95 (S-4). The Bottom Line: The pattern structure dictates the bias. Until SLDB can reclaim the breakdown level and stabilize, the path of least resistance remains a gravitational pull into the 200-day SMA liquidity pocket. Respect the breakdown and manage risk accordingly. NFA. Please do your own DD. $XBI $IWM $IBB
0 · Reply
Teillbou
Teillbou May. 15 at 11:26 PM
$SLDB 750M, $RGNX 370M For what exactly? RGX-202 Phase 3 just hit primary endpoint — 93% of patients above 10% microdystrophin expression p<0.0001. Statistically significant correlation with functional improvement. CT domain differentiation. 2+ years safety data. SGT-003 has biomarkers and a Phase 3 that just dosed its first patient — no NSAA, no timed tests published. Results won't come before 2028 at best. Market punishing RGNX on cash and FDA execution — fair. But $100M AbbVie coming Q2, wet AMD readout Q4. You're paying ~$120M above cash for all of that. SLDB you're paying $370M above cash for Phase 3 data years away. Make it make sense. $SLDB $DMD.X
2 · Reply
diggs24
diggs24 May. 15 at 8:44 PM
$SLDB 12714@$3.39
0 · Reply
millionaire2021
millionaire2021 May. 15 at 8:39 PM
$SLDB may I please ask your average ?
0 · Reply
diggs24
diggs24 May. 15 at 5:57 PM
$SLDB Added another 300 as it fell today. Up to 12,700 shares.
0 · Reply
Michael1965now
Michael1965now May. 15 at 10:53 AM
$SLDB Ignore the Pre-Market
0 · Reply
Jonrenie
Jonrenie May. 15 at 8:06 AM
$SLDB so this thing has been swinging hard for a while now. Someone is cleaning up. I’m going to be cycling some shares so they aren’t the only ones.
0 · Reply
pharmd2828
pharmd2828 May. 14 at 6:41 PM
$SLDB FA .. Frederick ataxia
0 · Reply
pharmd2828
pharmd2828 May. 13 at 4:04 PM
$SLDB be aware of whales actions !!
0 · Reply
Michael1965now
Michael1965now May. 13 at 2:49 PM
$SLDB the financial overhang is officially gone...this could get interesting.
0 · Reply
pharmd2828
pharmd2828 May. 12 at 8:27 PM
$SLDB solid reports solid earnings report!
0 · Reply
pharmd2828
pharmd2828 May. 12 at 3:41 PM
$SLDB short percentage has gone down to about 8% which is good!
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 11 at 11:09 PM
$SLDB RSI: 42.94, MACD: -0.0967 Vol: 0.58, MA20: 7.72, MA50: 7.46 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Michael1965now
Michael1965now May. 11 at 1:51 PM
$SLDB close to 10% short is considered above average. Potential for upward pressure this week is quite high. Being short now is considered high risk. Possible short squeeze is higher than normal.
0 · Reply
Michael1965now
Michael1965now May. 11 at 1:46 PM
$SLDB As of May 2026, Solid Biosciences (SLDB) has a moderate short interest of 9.78% of the public float, with ~9.4 million shares sold short. A short squeeze risk increases if the stock breaks above its 52-week high of $8.87, potentially triggering a rapid upward movement toward analyst targets of $12$26. KEY Short Squeeze Factors (May 2026):Short Interest: 9.44 million shares (9.78% of float).Days to Cover: 9.4, indicating it would take nearly 10 days to cover all short positions.Price Level: The stock recently traded around $7.27, with a 52-week high of $8.87. ANALYST Outlook: The average price target is over 130% higher than the current price (around $17), which may create pressure on shorts if positive clinical data or news drives the price up. A significant surge above the $8.87 resistance level could force short sellers to cover, especially given the high percentage of bullish, high-target analyst coverage
0 · Reply
pharmd2828
pharmd2828 May. 11 at 2:53 AM
0 · Reply
pharmd2828
pharmd2828 May. 8 at 11:03 PM
$SLDB next week presentations are exceptionally important for SLDB! This isn't just a routine check-in; it's the scientific validation of their entire next-generation platform (the POLARIS-101 capsid) at the exact moment they are moving into the final stages of clinical testing.
0 · Reply